ResApp Health Limited announced that it has secured a three year, non-exclusive licensing agreement with Janssen Pharmaceutica NV (Janssen), for the use of its ResAppDx technology in a respiratory syncytial virus (RSV) clinical trial. This agreement was facilitated by Johnson & Johnson Innovation. ResAppDx will be used in a clinical trial conducted by Janssen to assess the respiratory symptoms of a cohort of patients with a range of respiratory diseases, including RSV. In adults, RSV symptoms are typically mild and similar to the common cold, however in severe cases RSV can spread to the lower respiratory tract causing pneumonia or acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) or asthma. The trial will be conducted in the United States, Europe, South America and Asia-Pacific, and is expected to commence later this calendar year. Janssen will pay development and maintenance costs in addition to a fee per ResAppDx test to ResApp.